[Treatment of hypertension with a new beta blocker-diuretic combination under long-term control].
161 hospitalized hypertensive patients of all degrees of severity were treated with a dose of once daily 200 mg celiprolol for 3 weeks. The data of 143 patients were evaluated. After 3 weeks of therapy with 200 mg celiprolol 67,8% of the patients showed to be responders. 42 non responders were treated under double blind conditions for the following 3 weeks with 2 different dosages of chlorthalidone (12,5 mg or 25 mg CT) in combination with 200 mg celiprolol once daily. After 3 weeks of therapy 80,9% of the patients showed a satisfying reduction of blood pressure. There was no difference in terms of the extent of blood pressure reduction between the 2 combination treatment groups. A total of 73 patients who responded to celiprolol monotherapy or one of the combination therapies were treated up to 12 months. The data of 43 patients, who came to all monthly controls, could be evaluated. During the whole period of treatment a constant reduction of elevated blood pressure levels was obtained under treatment with 200 mg celiprolol or in combination with 12,5 mg or 25 mg CT. There was no negative influence on laboratory parameters under celiprolol or combination (12,5 mg CT) therapy. There was a slight increase of uric acid and in 3 cases a decrease of serum potassium under combination therapy with 25 mg CT.
Hoffmann
H
H
Hoffmann
W
W
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000494:pharmacology; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D017272:Celiprolol; D002752:Chlorthalidone / Q000008:administration & dosage* / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011412:Propanolamines / Q000008:administration & dosage* / Q000494:pharmacology; D013997:Time Factors; D014527:Uric Acid / Q000097:blood
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D014527:Uric Acid; D017272:Celiprolol; D002752:Chlorthalidone; D011188:Potassium
Hypertoniebehandlung mit einer neuen Betablocker-Diuretikum-Kombination unter Langzeitkontrolle.